226 related articles for article (PubMed ID: 26999239)
1. Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
Soysal P; Isik AT
J Nutr Health Aging; 2016 Apr; 20(4):398-403. PubMed ID: 26999239
[TBL] [Abstract][Full Text] [Related]
2. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
3. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S
Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233
[TBL] [Abstract][Full Text] [Related]
4. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
Mohammad D; Chan P; Bradley J; Lanctôt K; Herrmann N
Expert Opin Drug Saf; 2017 Sep; 16(9):1009-1019. PubMed ID: 28678552
[TBL] [Abstract][Full Text] [Related]
5. Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
Lai EC; Wong MB; Iwata I; Zhang Y; Hsieh CY; Kao Yang YH; Setoguchi S
J Am Geriatr Soc; 2015 May; 63(5):869-76. PubMed ID: 25912671
[TBL] [Abstract][Full Text] [Related]
6. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Isik AT; Bozoglu E; Yay A; Soysal P; Ateskan U
Am J Alzheimers Dis Other Demen; 2012 May; 27(3):171-4. PubMed ID: 22573283
[TBL] [Abstract][Full Text] [Related]
7. Galantamine improves sleep quality in patients with dementia.
Naharci MI; Ozturk A; Yasar H; Cintosun U; Kocak N; Bozoglu E; Tasci I; Doruk H
Acta Neurol Belg; 2015 Dec; 115(4):563-8. PubMed ID: 25777522
[TBL] [Abstract][Full Text] [Related]
8. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Shimohama S
Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
[TBL] [Abstract][Full Text] [Related]
11. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
Sicras A; Rejas-Gutiérrez J
Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
[TBL] [Abstract][Full Text] [Related]
12. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
[TBL] [Abstract][Full Text] [Related]
13. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
14. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
Taipale H; Tanskanen A; Koponen M; Tolppanen AM; Tiihonen J; Hartikainen S
Int Clin Psychopharmacol; 2014 Jul; 29(4):216-23. PubMed ID: 24608822
[TBL] [Abstract][Full Text] [Related]
15. Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review.
Moyaert P; Beun S; Achten E; Clement P
J Alzheimers Dis; 2023; 93(4):1211-1221. PubMed ID: 37182871
[TBL] [Abstract][Full Text] [Related]
16. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
17. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M; Eap CB
Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
[TBL] [Abstract][Full Text] [Related]
19. Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Nielsen RE; Grøntved S; Lolk A; Andersen K; Valentin JB
Medicine (Baltimore); 2022 Nov; 101(45):e31625. PubMed ID: 36397447
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil.
Rosenbloom MH; Brown J; Berlowitz DR; Budson AE
Consult Pharm; 2011 Feb; 26(2):108-10. PubMed ID: 21310708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
